EKSO vs ATAI

For growth investors, Atai Beckley N.

V (ATAI) is the stronger pick with -1. 9% revenue growth year-over-year, versus -28. 6% for Ekso Bionics Holdings, Inc. (EKSO). Analysts rate Ekso Bionics Holdings, Inc. (EKSO) a "Buy" — based on 4 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Atai Beckley N.

V (ATAI) delivered a total return of -79. 8%, compared to -85. 5% for Ekso Bionics Holdings, Inc. (EKSO). Over 10 years, the gap is even starker: ATAI returned -47. 7% versus EKSO's -99. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Atai Beckley N.

V (ATAI) is the lower-risk stock at 1. 48β versus Ekso Bionics Holdings, Inc. 's 2. 02β — meaning EKSO is approximately 36% more volatile than ATAI relative to the S&P 500. On balance sheet safety, Atai Beckley N. V (ATAI) carries a lower debt/equity ratio of 21% versus 29% for Ekso Bionics Holdings, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Atai Beckley N.

V (ATAI) is pulling ahead at -1. 9% versus -28. 6% for Ekso Bionics Holdings, Inc. (EKSO). On earnings-per-share growth, the picture is similar: Atai Beckley N. V grew EPS -272. 0% year-over-year, compared to -776. 8% for Ekso Bionics Holdings, Inc.. Over a 3-year CAGR, EKSO leads at -0. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Ekso Bionics Holdings, Inc.

(EKSO) is the more profitable company, earning -91. 4% net margin versus -484. 6% for Atai Beckley N. V — meaning it keeps -91. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: EKSO leads at -104. 1% versus -333. 4% for ATAI. At the gross margin level — before operating expenses — ATAI leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

In this comparison, EKSO (0.

8% yield) pays a dividend. ATAI does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Ekso Bionics Holdings, Inc.

(EKSO) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (0. 8% yield). Both have compounded well over 10 years (EKSO: -99. 3%, ATAI: -47. 7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

EKSO pays a dividend while ATAI does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.